Posted by on September 10, 2021 6:01 pm
Categories: News

Pfizer Partner to Seek Approval Soon for Vaccine for 5- to 11-Year-Olds: Executives

BioNTech, which developed one of the world’s most commonly used COVID-19 vaccines along with Pfizer, is attempting to gain approval soon for vaccinating children between the ages of 5 and 11 across the world, top executives with the firm announced Friday. “Already over the next few weeks we will file the results of our trial in 5- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told German publication Der Spiegel. She added that her firm is now working to produce the vaccine, which is merely the same drug that is administered in adults but at a smaller dose. “Things are looking good, everything is going according to plan,” said BioNTech’s chief executive, Ugur Sahin. In July, Israel, which heavily relies on the Pfizer-BioNTech vaccine, started administering doses in children aged 5 …

Originally appeared on The Epoch Times

Read More

Leave a Reply

Your email address will not be published.